Boehringer Ingelheim and HealthPrize Expand Successful Digital Patient Support Program
Summary
Activities include reporting daily medicine taking, verifying monthly refills, reading educational information and insightful tips and completing weekly quizzes and surveys. “We strongly support the role of innovative health technology solutions in respiratory treatment plans to help improve healthcare outcomes,” said Jean-Michel Boers, president Human Pharma Boehringer Ingelheim Pharmaceuticals Inc. “We partnered with HealthPrize to adapt their interactive patient solution, and we are very pleased with the impact of RespiPoints, which has made a positive difference in patients’ adherence to daily treatment plans and their understanding of the disease.” Results from the nine-month pilot of the RespiPoints program, which will also be presented today at the 2018 DTC National Conference in Boston, include: “The results from the RespiPoints program confirm the value of the HealthPrize platform to enroll and engage people who may need additional support to better understand and manage their health,” said Tom Kottler, co-founder and CEO, HealthPrize. Life science companies worldwide use HealthPrize’s technology to develop digital patient experiences that enhance revenue by improving adherence, increasing health literacy, and providing brand differentiation. The company’s gamification- and behavioral economics-based platform powers and advances patient engagement for branded and generic medications across all therapeutic areas, demographics and drug delivery methods. Since its founding in 1885, the company has remained family-owned and today creates value through innovation for three business areas including human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.